Ajanta Pharma Limited
AJANTPHARM
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 36.76 | 3.26% |
| 2025 | 35.60 | 3.07% |
| 2024 | 34.54 | 31.12% |
| 2023 | 26.34 | 19.93% |
| 2022 | 21.96 | -7.97% |
| 2021 | 23.86 | -6.39% |
| 2020 | 25.49 | 8.31% |
| 2019 | 23.53 | -10.60% |
| 2018 | 26.33 | -13.88% |
| 2017 | 30.57 | -1.04% |
| 2016 | 30.89 | -11.43% |
| 2015 | 34.88 | 133.25% |
| 2014 | 14.95 | 9.27% |
| 2013 | 13.69 | 97.10% |
| 2012 | 6.94 | 50.18% |
| 2011 | 4.62 | -26.14% |
| 2010 | 6.26 | 165.04% |
| 2009 | 2.36 | -45.13% |
| 2008 | 4.30 | -24.79% |
| 2007 | 5.72 | -17.47% |
| 2006 | 6.93 | 2.48% |
| 2005 | 6.77 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -4.90% |
IN
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.